Treatment of a patient with advanced esophageal cancer with a combination of mitomycin C and capecitabine: Activation of the thymidine phosphorylase as active principle?

Onkologie

Volumn 26, Issue 2, 2003, Pages 161-164

  Hofheinz, Ralf D ^a,b   Weisser, A ^a   Willer, A ^a   Hehlmann, R ^a   Hochhaus, A ^a  

^a MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Capecitabine; Chemotherapy; Esophageal cancer; Mitomycin C; Second line treatment

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; MITOMYCIN C; THYMIDINE PHOSPHORYLASE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; ENZYME ACTIVATION; ESOPHAGUS CANCER; HUMAN; HUMAN TISSUE; MALE; PROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME ACTIVATION; ESOPHAGEAL NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; THYMIDINE PHOSPHORYLASE; TREATMENT OUTCOME;

EID: 0038653493     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069837     Document Type: Article

References (27)

1. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B: Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-297.
2. Cassidy J, Twelves C, van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendrick J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-575.
3. Hong Y, Song S, Cho J, Lee S, Chung H, Choi S, Noh S, Park J, Han J, Kang J, Kee J: A phase II trial of capecitabine (Xeloda) in chemotherapy naive patients with advanced/metastatic gastric cancer. Proc Am Soc Clin Oncol 2002;21:623(abstr).
4. Stemmler J, Heinemann V, Schalhorn A: Capecitabine as second-line treatment of metastatic cholangiocarcinoma: A report of two cases. Onkologie 2002;25:182-184.
5. Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, Schulz JJ: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160-164.
6. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Müller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD: Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002;20:1759-1766.
7. Tabernero J, Butts CA, Cassidy J, Conroy T, de Braud F, Diaz-Rubio E, Figer A, Schoeffski P, Grossmann J, Sobrero A, Twelves C, van Cutsem E: Capecitabine and oxaliplatin in combination (Xelox) as first line therapy for patients with metastatic colorectal cancer (MCRC): Results of an international multicenter phase II trial. Proc Am Soc Clin Oncol 2002;21:531.
8. Vanhoefer U, Mayer S, Harstrick A, Achterrath W, Frings S, Deuss B, Wilke H, Seeber S: Phase I study of capecitabine in combination with a weekly schedule of irinotecan (CPT-11) as first-line chemotherapy in metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000;19:1059(abstr).
9. Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Lang F, Haider K, Kwasny W: Gemcitabine alone or in combination with capecitabine in patients with advanced pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 2002;21:500.
10. Hartmann JT, Harstrick A, Daikeler T, Kollmannsberger C, Müller S, Seeber S, Kanz L, Bokemeyer C: Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. Anticancer Drugs 1998;9:427-431.
11. Hartmann JT, Quietzsch D, Daikeler T, Kollmannsberger C, Mayer F, Kanz L, Bokemeyer C: Mitomycin C continuous infusion as salvage chemotherapy in patients with advanced gastric cancer. Anticancer Drugs 1999;10:729-733.
12. Hartung G, Hofheinz R, Buchheidt D, Rost A, Brecht A, Forche K, Schröder M, Wojatschek C, Fritze D, Hehlmann R, Queißer W: Combination of Bolus 5-fluorouracil, folinic acid and mitomycin C in advanced gastric cancer: Results of a phase II trial. Onkologie 2000;23:444-447.
13. Seitz JF, Perrier M, Giovannini G, Capodano G, Bernardini D, Bardou VJ: 5-Fluorouracil, high-dose folinic acid and Mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma. J Chemother 1998;10:258-265.
14. Becker K, Rinas U, Weidmann B, Heider A, Niederle N: High-dose 5-Fluorouracil/Folinic acid (HD-5-FU/FA) plus Mitomycin C in patients with refractory colorectal cancer. Proc Am Soc Clin Oncol 1997;16:1004(abstr).
15. Tassinari D, Arcangeli V, Panzini I, Sartori S, Gianni L, Ravaioli A: Can mitomycin C represent a valid partner for 5-fluorouracil in second-line chemotherapy of colorectal cancer? Ann Oncol 2000;11:1071.
16. Grumett SA, Archer VR, Midgley R, Mulholland P, Nicum S, Blewitt L, Kerr DJ: The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy. Ann Oncol 2001;12:575.
17. Chester JD, Dent JT, Wilson G, Ride E, Seymour MT: Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Ann Oncol 2000;11:235-237.
18. Conti JA, Kemeny NE, Saltz LB, Andre AM, Grossano DD, Bertino JR: Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as salvage regimen for patients with colorectal cancer. J Clin Oncol 1995;75:769-774.
19. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R, Oates J: A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without Mitomycin C in advanced colorectal cancer. Ann Oncol 1997;8:995-1001.
20. Price T, Cunningham D, Hickish T, Tait D, Norman A, Ross PJ, Middleton G, Ford HER, Sumpter K: Phase III study of chronomodulated vs protracted infusional 5-fluorouracil both combined with mitomycin C in first line therapy for advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1999;18:1008(abstr).
21. Kretzschmar A, Reichardt P, Thuss-Patience PC, Hohenberger P, Benten T, Dörken B, Köhne CH: Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer. Oncology 2000;59:14-17.
22. Hofheinz R, Hartung G, Samel S Hochhaus A, Pichlmeier U, Post S, Hehlmann R, Queisser W: High-dose 5-fluorouracil/folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase-II study. Onkologie 2002;25:255-260.
23. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Scarffe JH, Anderson H, Iveson T, Hickish T, Lofts F, Norman A: Prospective randomized trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004.
24. Yamshita K, Tsunoda T, Urakami A, Iwamoto S, Kimoto M, Iki K, Hayashi J, Oka Y, Fujikura H, Ikeda M, Hirabayashi Y: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by mitomycin c in human colorectal cancer. Proc Am Assoc Clin Oncol 2001;20:600(abstr).
25. Sawada N, Ishikawa T, Fukase Y, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Cin Cancer Res 1998;4:1013-1019.
26. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Shailendra Verma S, Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
27. Rusello O, Romanini A, Civalleri D, Rosso R, Nicolin A, Sobrero A: Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon cancer cell line, HCT-8 in vitro. Eur J Cancer Clin Oncol 1998;25:1598-1603.